IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:* an aromatase inhibitor as initial endocrine-based therapy: or* fulvestrant in patients with disease progression following endocrine therapy.